LisaACareyMD

Oncology • Chapel Hill, NC

Professor of Hematology & Oncology, University of North Carolina School of Medicine

Join to view full profile

Dr. Carey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Carey's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 984-974-0000

Fax+1 919-966-7772
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1997
Johns Hopkins UniversityResidency, Internal Medicine, 1990 - 1993
Johns Hopkins University School of MedicineClass of 1990

Certifications & Licensure

NC State Medical License 1997 - 2024
MD State Medical License 1993 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013

Clinical Trials

Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer Start of enrollment: 1998 Dec 01
Completed
Phase 2
Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 2
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Start of enrollment: 2008 Jun 18
Completed
Phase 2
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior Start of enrollment: 1998 Dec 01
Recruiting
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 Start of enrollment: 2012 Jan 01
Completed
Early Phase 1
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib Start of enrollment: 2013 Aug 05
Completed
Early Phase 1
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer Start of enrollment: 2014 Jan 30
Active, not recruiting
Phase 2
The Impact of a Physical Activity Program on Biomarkers of Aging During Chemotherapy for Breast Cancer Start of enrollment: 2014 Mar 01
Completed
The Effect of Walking on Fatigue After Chemotherapy in Patients 65 and Older Start of enrollment: 2014 Jun 01
Completed
Not Applicable
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Start of enrollment: 2020 Sep 23
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
Sara A Hurvitz, Kevin Punie, Véronique Diéras, Rosemary Delaney, Yanni Zhu, Aditya Bardia, Kevin Kalinsky, Lisa A Carey, Hope S Rugo, See Phan, Sara M Tolaney> ;NPJ Breast Cancer. 2024 Apr 25
Global post-mortem tissue donation programmes to accelerate cancer research.
Christine Desmedt, Lisa A Carey> ;Nature Reviews. Cancer. 2024 Apr 8
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
Iseult M Browne, Fabrice André, Nicholas C Turner, Sarat Chandarlapaty, Lisa A Carey> ;The Lancet. Oncology. 2024 Apr 1
1 citations
Research autopsy programmes in oncology: shared experience from 14 centres across the world.
Tatjana Geukens, Marion Maetens, Jody E Hooper, Steffi Oesterreich, Adrian V Lee, Lori Miller, Jenny M Atkinson, Margaret Rosenzweig, Shannon Puhalla, Heather Thorne, ...> ;The Journal of Pathology. 2024 Mar 29
BIRC5 expression by race, age and clinical factors in breast cancer patients.
Alina M Hamilton, Andrea Walens, Sarah C Van Alsten, Linnea T Olsson, Joseph Nsonwu-Farley, Xiaohua Gao, Erin L Kirk, Charles M Perou, Melissa A Troester, Lisa A Carey...> ;Breast Cancer Research. 2024 Mar 21
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Fac...
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Kevin Kalinsky, Javier Cortés, Joyce O' Shaughnessy, Véroniqu...> ;Journal of Clinical Oncology. 2024 Feb 29
Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast...
Zagami, P., Fernandez-Martinez, A., Rashid, N., Hoadley, K., Spears, P., Curigliano, G., Perou, C., Carey, L.> ;JAMA Network Open. 2023 Dec 1
Cardiotoxicity of Agents Used in Patients With Breast Cancer.
Paola Zagami, Dario Trapani, Eleonora Nicolò, Chiara Corti, Carmine Valenza, Carmen Criscitiello, Giuseppe Curigliano, Lisa Anne Carey> ;JCO Oncology Practice. 2024 Jan 1
1 citations
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A Hoadley, Joel S Parker, Baljit Singh, Jordan D Campbell, Karla V Ballman, David W...> ;Nature Communications. 2023 Nov 3
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing i...
Beverly Moy, Antonio C Wolff, R Bryan Rumble, Kimberly H Allison, Lisa A Carey> ;JCO Oncology Practice. 2023 Aug 1
38 citations
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
P Tarantino, G Viale, M F Press, X Hu, F Penault-Llorca, A Bardia, A Batistatou, H J Burstein, L A Carey, J Cortes, C Denkert, V Diéras, W Jacot, A K Koutras, A Lebeau...> ;Annals of Oncology. 2023 Aug 1
2 citations
Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.
Benjamin G Vincent, Danielle M File, Karen P McKinnon, Dominic T Moore, Jeffrey A Frelinger, Edward J Collins, Joseph G Ibrahim, Lisa Bixby, Shannon Reisdorf, Sonia J ...> ;Journal of Immunology. 2023 Jul 15
Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors.
Tal Sella, Yue Zheng, Shoshana M Rosenberg, Kathryn J Ruddy, Shari I Gelber, Rulla M Tamimi, Jeffrey M Peppercorn, Lidia Schapira, Virginia F Borges, Steven E Come, Li...> ;NPJ Breast Cancer. 2023 Apr 25
17 citations
Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance).
Judy C Boughey, Kari M Rosenkranz, Karla V Ballman, Linda McCall, Bruce G Haffty, Laurie W Cuttino, Charlotte D Kubicky, Huong T Le-Petross, Armando E Giuliano, Kimber...> ;Journal of Clinical Oncology. 2023 Jun 10
3 citations
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Heather A Parsons, Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana G Abramson, Ashka Patel, Ju Cheng, Adam Brufsky, Justin Rhoade...> ;Medrxiv. 2023 Mar 8
35 citations
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Tolaney, S., Tarantino, P., Graham, N., Tayob, N., Parè, L., Villacampa, G., Dang, C., Yardley, D., Moy, B., Marcom, P., Albain, K., Rugo, H., Ellis, M., Shapira, I., ...> ;The Lancet. Oncology. 2023 Mar 1
2 citations
A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, accep...
Zev M Nakamura, Allison M Deal, Eliza M Park, Kate E Stanton, Yesy E Lopez, Laura J Quillen, Erin O'Hare Kelly, Hillary M Heiling, Kirsten A Nyrop, Emily M Ray, E Clai...> ;Cancer Medicine. 2023 Apr 1
6 citations
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
Beverly Moy, R Bryan Rumble, Lisa A Carey> ;Journal of Clinical Oncology. 2023 Feb 20
15 citations
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Corr...
Aranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, Paolo Nuciforo, Naim U Rashid, Karla V Ballman, Jordan D Campbell, Katherine A Hoadley, Patricia A Spears, La...> ;JAMA Oncology. 2023 Apr 1
28 citations
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
Susana Garcia-Recio, Toshinori Hinoue, Gregory L Wheeler, Benjamin J Kelly, Ana C Garrido-Castro, Tomas Pascual, Aguirre A De Cubas, Youli Xia, Brooke M Felsheim, Marn...> ;Nature Cancer. 2023 Jan 1
Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metas...
G Curigliano, V Mueller, V Borges, E Hamilton, S Hurvitz, S Loi, R Murthy, A Okines, E Paplomata, D Cameron, L A Carey, K Gelmon, G N Hortobagyi, I Krop, S Loibl, M Pe...> ;Annals of Oncology. 2023 Jul 1
4 citations
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.
Kala Visvanathan, Leslie Cope, Mary Jo Fackler, Michael Considine, Lori Sokoll, Lisa A Carey, Andres Forero-Torres, James N Ingle, Nancy U Lin, Rita Nanda, Anna Maria ...> ;Clinical Cancer Research. 2023 Feb 16
43 citations
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Bra...
Nancy U Lin, Rashmi K Murthy, Vandana Abramson, Carey Anders, Thomas Bachelot, Philippe L Bedard, Virginia Borges, David Cameron, Lisa A Carey, A Jo Chien, Giuseppe Cu...> ;JAMA Oncology. 2023 Feb 1
25 citations
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors.
Yara Abdou, Atta Goudarzi, Jia Xin Yu, Samik Upadhaya, Benjamin Vincent, Lisa A Carey> ;NPJ Breast Cancer. 2022 Nov 9
13 citations
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
Sibylle Loibl, Delphine Loirat, Sara M Tolaney, Kevin Punie, Mafalda Oliveira, Hope S Rugo, Aditya Bardia, Sara A Hurvitz, Adam M Brufsky, Kevin Kalinsky, Javier Corté...> ;European Journal of Cancer. 2023 Jan 1
Join now to see all

Journal Articles

Integrated Analysis of RNA and DNA from a Phase III Trial of Trastuzumab-Based Neoadjuvant Chemotherapy Identifies Response Predictors in HER2-Positive Breast Cancer
Lisa Carey, MD, Clinical Cancer Research

Lectures

HER2-Targeted Therapy: Changing the Story of Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Authored Content

Key Immunotherapy Presentations in Early Breast Cancer from ESMO 2023: KEYNOTE-756, CheckMate-7FL, and Updated KEYNOTE-522October 2023
Endocrine-Based Therapy for Early and Metastatic Breast Cancer: New Horizons from ASCO 2023June 2023

Press Mentions

Association of Immune-Related Gene Expression Signatures and TILs with Outcomes in Early-Stage HER2-Positive Breast CancerJanuary 31st, 2023
Immune-Related Biomarkers Can Help Guide HER2+ Breast Cancer TxJanuary 24th, 2023
Study Identifies Molecular Differences Between Primary Breast Cancer and Its MetastasesJanuary 9th, 2023
Join now to see all

Grant Support

Breast Cancer ResearchNational Cancer Institute2011–2012
Academic Training In Oncology At The University Of North Carolina At Chapel HillNational Cancer Institute2011
Developmental Research ProgramNational Cancer Institute2006–2010
Lccc 0403: Phase II Cetuximab Alone And In Combination With CarboplatinNational Center For Research Resources2007
Lccc 9818: Stage IIB, Stage IIIA/B Stage IV Breast CancerNational Center For Research Resources2004–2006
Correlation Of Marker With Response To ChemotherapyNational Cancer Institute2001–2002
Tamoxifen &Raloxifene For Preventtion Of Breast CancerNational Center For Research Resources2000
Molecular Markers W/ Response To Chemotherapy In Breast CANational Center For Research Resources2000
Doxorubicin &Cyclophosphamide &Paclitaxel W/ HerceptinNational Center For Research Resources2000